ArticleCureus2026
Antibody Responses to SARS-CoV-2 in Cancer Patients in New York City During the 2020 Wave of the COVID-19 Pandemic.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNew York City was the epicenter of the first wave of the COVID-19 pandemic, and cancer patients were among the most vulnerable groups. We characterized antibody response in a diverse cohort of cancer patients prior to the availability of COVID-19 therapeutics. We report: (1) antibody response to COVID-19 by cancer type; (2) trend of SARS-CoV-2 IgG spike antibodies over time in cancer patients with COVID-19 diagnosis during 2020-2021.
methodsSingle-center, prospective, observational study of patients treated for cancer at Memorial Sloan Kettering Cancer Center with symptomatic, laboratory-confirmed COVID-19. Serial blood specimens were collected after COVID-19 diagnosis and before administration of any COVID-19 vaccine or monoclonal antibody. IgG was determined using the AdviseDx SARS-CoV-2 IgG II assay. Antibody response was defined as a titer ≥50 AU/mL. Early antibody response was defined as <14 weeks, and late antibody response as >14 weeks after COVID-19 diagnosis. Group comparisons were performed using the Wilcoxon rank-sum test, while Fisher's exact or chi-squared tests and ANOVA were used for categorical comparisons. A locally estimated scatterplot smoothing technique and a linear mixed-effects model were applied to assess the trend in IgG titers over time.
resultsOf 245 patients analyzed, 127 (51.9%) had solid tumors and 118 (48.1%) hematologic malignancies. Among patients with hematologic malignancies, 15 received B-cell-depleting therapies within 6 months of COVID-19 diagnosis. Overall, 181 (87%) patients had early antibody response, including 97 (92%) patients with solid tumors, 77 (88%) with hematologic malignancies without B-cell-depleting therapies, and 7 (50%) with hematologic malignancies who received B-cell-depleting therapies. The magnitude of early antibody response was significantly lower in patients who received B-cell-depleting therapies compared to both other groups. A total of 452 specimens were analyzed to evaluate the trend of IgG titers over time. A measurable decline is observed over time, with an estimated 14.437 AU/mL decrease per day post-COVID-19 diagnosis (p <0.001).
conclusionOverall, 87% of cancer patients had an early antibody response to COVID-19. Only 50% of patients with hematologic malignancies who received B-cell-depleting therapies developed an antibody response, and IgG titers were significantly lower in this group compared to both patients with solid tumors and patients with hematologic malignancies without B-cell-depleting therapies. We observed a progressive decline in IgG titers over time, with an estimated decrease of 14.437 AU/mL per day post-COVID-19 diagnosis. These findings offer valuable insights into antibody responses in cancer patients following COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.